Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Slides:



Advertisements
Similar presentations
PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014.
Advertisements

What is it? How may it help women? PrEP. What is PrEP? How would it work? What do we know about it? When will we know more? What could it mean for women?
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Hadiyah Charles, Community HIV/AIDS Mobilization Project Naina Khanna, WORLD/U.S. Positive Women’s Network HIV Research Catalyst Forum April 21, 2010.
HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College.
Potential role of PEP, PrEP and ART for HIV Prevention among Men who have Sex with Men Frits van Griensven, PhD, MPH Division of HIV/AIDS Prevention US.
New York State Department of Health AIDS Institute June, 2014
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Use of Antivirals in Prevention Oral and Topical Prophylaxis
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
The potential and challenges of ARV-based HIV prevention: An overview
Can we prevent infection after an exposure
The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Introduction to HIV New Prevention Technologies (NPTs)
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington.
Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
MSM 2003HIV positive 17 % 2005HIV positive 28 % 2007HIV positive 32 %
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
The Microbicide Trials Network Group 3 Lindsay O. Bryant Danielle M. Campbell Alan D. Johnson Leroy Smith Jr. Kendra M. Taylor May 31, 2016.
Ethics in a new era Microbicides 2012 Preconference Bridget Haire.
Michael Hughes, MD Assistant Clinical Professor UCR Eisenhower Medical Associates.
Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modeling approach Dawn K.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,
A pill to prevent HIV? For women??
New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
New Prevention Technologies Workshop Module 2: NPTs in context
ARV-Based Prevention What it means for women Your name here
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
The tipping point: When do placebos become unethical? Bridget Haire.
BRADFORD BRIGGS & NIKE JACKSON. BRADFORD BRIGGS Prevention Toolbox.
Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.
Session: Treatment is Prevention? 16 th International Conference on AIDS and Sexually Transmitted Infections in Africa, Addis Ababa, Ethiopia Catherine.
Information about HIV Prevention Options
IAS Satellite Session 25th July 2017 Daniel Were, PhD
PrEP for HIV Prevention
Preexposure Prophylaxis (PreP) for the Prevention of HIV
Module 4 (c) Stopping PrEP
A protocol in development IMPAACT Prevention Scientific Committee
Rectal Microbicides: Where We’re Heading
On behalf of The MTN-020/ASPIRE Study Team
PrEP as an HIV Prevention Tool in Queer Communities of Color: Barriers and Opportunities BACKGROUND Joanne Stekler, MD MPH.
Tenvir-Em Tenvir EM is a generic version of Truvada and is used as part of a regiment of antiretroviral medications to treat HIV-1 in adults over 18. Each.
On Demand PrEP for Men at High Risk for HIV IPERGAY
Quarraisha Abdool Karim, PhD
MTN-025 (HOPE Study) Community Education Presentation
PrEP: A Case-by-Case Approach
PrEP introduction for Adolescent Girls and Young Women
The Possibilities of PrEP: Introduction
PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.
Pre-Exposure Prophylaxis (PrEP) for HIV Infection
PrEP Pre-Exposure Prophylaxis
PrEP.
Rectal Gels for PrEP Are They an Option?
100 Partners PrEP[5] Efficacy 75% Adherence 81% 80
José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member
Bob Holtkamp, Director of Prevention & Outreach
Presentation transcript:

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection

Turning to antiretrovirals for prevention The use of antiretrovirals for prevention by… 1. HIV-positive individuals to reduce their risk of transmitting HIV Treatment as prevention 2. HIV-negative individuals to reduce their risk of infection Post-exposure prophylaxis (PEP) Pre-exposure prophylaxis (PrEP)

What is pre-exposure prophylaxis (PrEP)? Pre  Before (and after) Exposure  When a fluid containing HIV comes into contact with mucous membranes or non-intact skin Prophylaxis  An action taken to prevent infection or disease

What is PrEP to prevent HIV infection? The ongoing use of one or two antiretrovirals by HIV- negative individuals starting before an exposure and continuing afterwards A potential option to prevent infection from ongoing exposures to HIV during periods of risk A recently proven strategy still being studied

How does PrEP work? Infection does not occur instantly after an exposure to HIV The virus needs to spread throughout the body This may take up to 3 days after the exposure The “window of opportunity” for PrEP The brief period of time - after an exposure - where HIV has not yet spread throughout the body During this time, PrEP may be able to stop HIV from causing an infection

Potential types of PrEP How are the antiretrovirals used? Oral pill Topical gel (microbicide) Rectal Vaginal Injection Intravaginal ring How often are the antiretrovirals used? Daily Intermittently Coitally (before/sex) How many antiretrovirals are used? Single Combination What antiretrovirals are used? Over 25 available

What concerns does the use of PrEP raise? Side-effects and toxicity Drug resistance Adherence Risk compensation Access Cost

What’s being researched? Large studies Viread or Truvada pill taken daily Viread  Tenofovir Truvada  Tenofovir + Emtricitabine Tenofovir vaginal gel used before/after sex or daily Small Studies Gels used rectally Pills used intermittently or before/after sex Slow-release intravaginal rings Long-lasting injections Antiretrovirals other than Tenofovir and Emtricitabine

How is the research conducted? Biomedical prevention trials Enrollment criteria Randomized Placebo-controlled Blinded Comprehensive package of prevention services Risk-reduction counseling Access to male and female condoms Adherence counseling HIV testing STI diagnosis and treatment Several outcomes measured HIV infections Adherence Side-effects and toxicity Risk behavior

10 What does the research say about PrEP? CAPRISA 004iPrExFEM-PrEPTDF2Partners PrEP Study participants Heterosexual women Men who have sex with men & transgender women Heterosexual women Heterosexual men and women Serodiscordant heterosexual couples Type of PrEPCoital tenofovir gel (vaginal) Daily Truvada pill Daily Viread pill Daily Truvada pill Reduced risk of HIV infection 39%44%0%63%62%(Viread)7 3% (Truvada) Consistent users 54%73%-78%- Safety concerns Diarrhea Nausea Headache Decrease in kidney fn and bone density Drug resistance No major safety concerns Nausea Vomiting Dizziness Nausea Diarrhea 10

Impact outside of a clinical trial 1. Uptake How many people are using it? Awareness – Do people know its available? Acceptability – Do people want to use it? Access – Can people access it if they want to? Who is using it? 2. Adherence Are people using it consistently and correctly? 3. Risk behavior Are people increasing their risk behavior?

What we do know about PrEP? In combination with a comprehensive package of prevention services… 1. Daily Truvada reduced the risk of infection when used by MSM and trans women Heterosexual men and women 2. Daily Viread reduced the risk of infection when used by heterosexual men and women 3. A vaginal tenofovir gel used before and after sex reduced the risk of infection when used by women. It needs to be used consistently for it to work. The risk of side effects, toxicity, and drug resistance are low.

What don’t we know about PrEP? Safety/effectiveness of… A pill taken occasionally A gel used in the rectum Long-lasting options (intravaginal ring or injection) Other antiretrovirals Safety/effectiveness of Viread, Truvada and tenofovir gel… In populations not included in trials Over a longer period of time In the “real world”

There is no magic pill